Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV:
LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech
company that leverages advancements in science and technology to
enable you to find your path to wellness, today announced that its
newly launched biosciences and consumer wellness subsidiary, Mikra
Cellular Sciences Inc. (“Mikra”), is poised to launch its first
product “CELLF”, a novel cellular therapeutic compound targeting
systemic fatigue. As part of pre-launch activities of CELLF, Mikra
has filed a patent application with the United States Patent and
Trademark Office and partnered with InVivo Biosystems, Inc.
(“InVivo Biosystems”) for pre-clinical trials to strengthen its
patent claim.
“The real health crisis isn’t reduced longevity
— we’re living longer than we have in the past. It’s extended
morbidity that’s the problem. While we’re all familiar with
mortality, morbidity is attributable to age-related diseases that
lower your quality of life which is why so many of us when we hit
our 30’s, 40’s and 50’s experience multiple physiological and
mental walls — notably brain fog, fatigue, and inflammation. This
all happens at a cellular level, and it can cascade into poor
sleep, mood drops, and an inability to enjoy life like you want
to,” said Faraaz Jamal, COO of Lifeist and CEO of Mikra. “With that
in mind, I’m extremely excited to present Mikra’s first product,
CELLF (pronounced “self”). We engineered this product for everyone
who has started to feel like their biological age is affecting
their everyday performance and ability to feel like the best
version of themselves.”
Continued Jamal, “CELLF works at a cellular
level to help combat systemic fatigue, inflammation, and brain fog
by promoting the creation of mitochondria and subsequently
increasing their efficiency. This is in addition to the
upregulation and downregulation of certain cellular detoxification
pathways that can remove the buildup of senescent
(old/dysfunctional) cells that may cause excessive chronic
inflammation and uncontrolled cell division.”
CELLF - A science-backed cellular
therapeutic, treating systemic fatigue and low-grade cellular
inflammation
CELLF is manufactured in a proprietary
oxygen-deprived environment to maintain biopotency and
bioavailability with clinically tested United States Food &
Drug Administration (FDA) certified GRAS (generally recognized as
safe) bioactive ingredients. The CELLF compound delivery system is
a two-stage, patented mechanism — it is first bound to a
transferrin glycoprotein and then encapsulated within a liposome.
This allows safe passage of CELLF through the gastric environment
and delivery directly into the blood plasma. The result is optimal
delivery of our compound with minimal degradation to the best site
of absorption. CELLF will be shipped in a package containing 30 X
10ml single-serve sachets to prevent oxidation and maximize
bioavailability.
“You’ve got to satisfy two conditions for a
product like this to work. The first is that the molecules within
the compound need to be backed by rigorous science. The second is
that you need to deliver it effectively into your body, and more
specifically, your cells so that it is maximally absorbed. Very few
products satisfy the first, let alone the second,” said Jamal. “As
one of my lifelong heroes, Carl Sagan once said, ‘extraordinary
claims require extraordinary evidence’, which is why we’ve
partnered with Invivo Biosystems to prove and strengthen our patent
claim that CELLF does both.”
Mikra Partners with InVivo
Biosystems
Mikra has partnered with InVivo Biosystems,
experts in genetic model creation and in vivo testing, to
strengthen its patent application by conducting a pre-clinical
study identifying genetic signatures and pathways associated with
average human healthspans and to test the effects of CELLF on
healthy aging.
“We are proud to partner with Mikra in
developing a family of healthy living products that reduce
biological aging. At InVivo Biosystems, we take a systematic,
multi-omics approach to make gene-by-gene discoveries and uncover
the different genetic pathways that are up or down regulated during
aging. The InVivo Longevity Platform measures the complex interplay
of cellular proliferation, autophagy, mitochondrial oxidative
stress, genetic predisposition, and transcriptional changes that
occur during aging,” said Chris Hopkins, PhD, Chief Science Officer
at InVivo Biosystems. “In our collaboration with Mikra, we are
exploring how its flagship formulation, CELLF, increases the
efficiency of mitochondrial ATP production and cellular
respiration. Using the InVivo Longevity Platform, we measure at the
molecular level how Mikra’s CELLF formulation can counter periodic
bouts of fatigue by providing improved cellular respiration. In our
partnership, we will be generating the science-based evidence that
Mikra can use as further backbone for their intellectual property
claims. Here at InVivo Biosystems we are also excited to continue
partnering with Mikra in the future to uncover further how CELLF,
and their future product lines, can create a new baseline for
healthy living after 30.”
CELLF Product & Community
Launch
“I’m very excited about adding incremental value
to Lifeist shareholders and unlocking the earnings potential of
Mikra and subsequently Lifeist. We’re taking the first steps here
with bringing something novel to the market, validating and
protecting it. But let’s be clear, it’s only the first step,” said
Meni Morim, CEO of Lifeist. “The initial traction Mikra has had
around the pre-launch has been very promising — to grow to a
community of nearly 20,000 with a huge level of engagement, in such
a short amount of time and with no sign of stopping is a testament
to the team’s expertise and validates the consumer’s desire for
this type of product.”
Mikra’s CELLF will be available for pre-sale in
mid-Q1 2022 with a waitlist sign up available at
www.wearemikra.com. CELLF will be available on www.wearemikra.com
and Amazon following the pre-sale for full public launch.
Follow Mikra’s journey on your favorite social
media platform with @wearemikra.
About Mikra, Cellular Sciences
Inc.Mikra is a biological sciences and consumer wellness
company on a mission to increase your healthspan by focusing on the
tiniest aspect of your health: the cell. People are made up of over
37 trillion cells with a variety of different sizes, shapes,
functions and lifespan. These cells are responsible for energy,
happiness, recovery potential and so much more. Mikra is exploring
the link between changes at a cellular level and the cascading
effects it can have on health.
About InVivo Biosystems,
Inc.InVivo Biosystems, an expert in genetics, delivers
scientific proof and evidence for ingredients at the molecular and
cellular level via a proprietary analytical approach. Its
analytical platform helps branded ingredient developers and
manufacturers substantiate their product claims, file IP patents,
or refine their formulations using the best science backed measure
of outcome. Managed by experienced PhD scientists, InVivo
Biosystems’ gene expression platform can help find new applications
for novel ingredients, discover new molecules, and conduct
proof-of-concept studies for therapeutic purposes. Visit
www.invivobiosystems.com/longevity for more information.
About Lifeist Wellness
Inc.Sitting at the forefront of the post-pandemic wellness
revolution, Lifeist is a portfolio of wellness companies leveraging
advancements in science and technology to enable individuals to
find their personalized path to wellness. Portfolio business units
include: CannMart, which operates a B2B wholesale distribution
business facilitating recreational sales to Canadian provincial
government control boards and the CannMart.com marketplace which
provides Canadian medical customers with a diverse selection of
cannabis products from a multitude of federally licensed
cultivators and its U.S. customers with access to hemp-derived CBD
and smoking accessories; Australian Vapes, the country’s largest
online retailer of vaporizers and accessories; Findify, a leading
AI-powered search and discovery platform; and Mikra, a biosciences
and consumer wellness company seeking to develop innovative
therapies for cellular health and recovery.
Information on Lifeist and its businesses can be
accessed through the links below:www.lifeist.com www.cannmart.com
www.everyonedoesit.co.uk www.australianvaporizers.com.au
www.wearemikra.com
Contacts
Lifeist Wellness Inc.Meni Morim, CEOMatt
Chesler, CFA, Investor RelationsPh: 647-362-0390Email:
ir@lifeist.com
Forward Looking Information
This news release contains “forward-looking
information” within the meaning of applicable securities laws. All
statements contained herein that are not historical in nature
contain forward-looking information. Forward-looking information
can be identified by words or phrases such as “may”, “expect”,
“likely”, “should”, “would”, “plan”, “anticipate”, “intend”,
“potential”, “proposed”, “estimate”, “believe” or the negative of
these terms, or other similar words, expressions and grammatical
variations thereof, or statements that certain events or conditions
“may” or “will” happen.
The forward-looking information contained
herein, including, without limitation, statements related to the
launch of Mikra’s first product “CELLF” and its anticipated
therapeutic benefits, are made as of the date of this press release
and is based on assumptions management believed to be reasonable at
the time such statements were made, including, without limitation,
expectations that pre-clinical trials will prove successful and
that the Company’s application for a patent will be granted,
expectations that CELLF will gain market acceptance along with the
expansion of the market for nutraceutical products and management’s
perceptions of Lifeist’s standing in the online marketplace for
wellness and related products, Lifeist’s beliefs regarding the
expected demand for wellness and related products and the expected
growth of that market, the timing of product availability, as well
as other considerations that are believed to be appropriate in the
circumstances. While we consider these assumptions to be reasonable
based on information currently available to management, there is no
assurance that such expectations will prove to be correct. By its
nature, forward-looking information is subject to inherent risks
and uncertainties that may be general or specific and which give
rise to the possibility that expectations, forecasts, predictions,
projections or conclusions will not prove to be accurate, that
assumptions may not be correct and that objectives, strategic goals
and priorities will not be achieved. A variety of factors,
including known and unknown risks, many of which are beyond our
control, could cause actual results to differ materially from the
forward-looking information in this press release. Such factors
include, without limitation: unforeseen developments that would
delay the Company’s ability to launch CELLF as anticipated and in a
timely manner, the risk that pre-clinical trials are not as
successful as anticipated and do not demonstrate anticipated
therapeutic benefits and/or fail to strengthen the Company’s patent
claim, the risk that the expected demand for nutraceutical products
in general and those of the Company does not develop as
anticipated, regulatory risk, risks relating to the Company’s
ability to execute its business strategy and the benefits
realizable therefrom and risks specifically related to the
Company’s operations. Additional risk factors can also be found in
the Company’s current MD&A and annual information form, both of
which have been filed under the Company’s SEDAR profile at
www.sedar.com. Readers are cautioned not to put undue reliance on
forward-looking information. The Company undertakes no obligation
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as
required by applicable law. Forward-looking statements contained in
this news release are expressly qualified by this cautionary
statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release or has in any way approved
or disapproved of the contents of this press release.
Source: Lifeist Wellness Inc.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/0629e54e-48ba-4759-a4ce-344d1b6cc525
https://www.globenewswire.com/NewsRoom/AttachmentNg/4e7b131b-e5d1-4e28-a67d-7fb10c3f7dba
https://www.globenewswire.com/NewsRoom/AttachmentNg/2f4c14b5-6aa9-44f9-8553-648e1e96a21a
Lifeist Wellness (TSXV:LFST)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lifeist Wellness (TSXV:LFST)
Historical Stock Chart
From Apr 2023 to Apr 2024